It has been well documented that preeclampsia (PE) has a common etiological background, but little is known about its linkage at the molecular level.Non-coding RNAs are critical posttranscriptional regulators ofgene expression. This study was performed to determine whether PE is associated with alterations in placental noncoding RNAs expression. MicroRNA (miR)-155-5p and long non-coding RNA (lnc)sONE expression, in placentas collected sequentially from 59 patients with PE and 40 normotensive pregnancies were measured using real-time PCR.The relationship between miR-155-5p and lncsONE expressions was analyzed statistically. miR-155-5p expression was increased (fold change =1.6, P=0.04), while lncsONE expression was not significantly changed (fold change =1.1, P=0.68), in placentas from patients compared with control group.miR-155-5p was upregulated in placentas from patients with PE and may have influenced eNOS expression. These findings indicate that miRNA-155-5p may be involved in PE pathogenesis and could be a potential biomarker for this disease.
espite remarkable progress in the prenatalogy science, pre-eclampsia (PE), a syndrome affecting 5-7% of pregnancy disorders, still remains as the most prevalent cause of maternal and fetal morbidity and mortality (1) . According to the WHO definition, PE is a pregnancy-related syndrome characterized by hypertension (greater than or equal to 140/ 90) and proteinuria (greater than or equal to 300 mg in a 24 h urine specimen) following 20 weeks of gestation (2) . Based on the elusive pathophysiology, PE has traditionally been called the disease of theories (3, 4) . Although, the association between the pathology of PE and (methyl tetrahydrofolate gene and V-leiden), free radical metabolism networks, and genes related to placentation, has been evaluated in numerous studies, unfortunately, none of these investigations were successful to introduce a main factor for the disease (2, 5) . Since the only way to treat PE is termination of pregnancy, hence the presence and the function of the placenta in development of PE is considerable and therefore it can be a main clue of changes in PE (5) . In order to prevent and treatPE, numerous experiments have been performed in both animal and human models using NO donors such as organic nitrates and NO precursors like L-Arginine (5, 6) . Production and function of NO is important in normal and PE pregnanciesfor the following reasons:i) Dysfunction of placenta endothelium, as a main initiating mechanism,may occur as a result of oxidative stress, which is characterized by decreased NO production and hypoxia. ii) It has been indicated that the production level of superoxide anion and other alternative metabolites of NO production pathway, including ornithine and asymmetric dimethylarginine (ADMA) is increased in the serum of patients, which could be considered as an early stage biomarker for the disease. iii) Several novel therapeutic approaches are affecting NO production pathway (4, 6, 7) . In endothelial cells, NO is encoded by eNOS3, which is negatively regulated through a multitude of molecules, including non-coding RNAs (mir-155) and lncRNAsONE. miRNA, single strand and ~22-nucleotide-long non-protein coding RNAs, are able to regulate gene expression by destabilizing the mRNA or down-regulating their target genes (8) . Mir-155 is the product of the polygenic conserved region of B-cell integration cluster gene, which is composed of 3 exons and located in chromosome 21q21 (9) . Evidences indicated that mir-155 was up-regulated in the collection of placenta from a large number of pregnant women suffering from PE. Indeed, eNOS is considered to be one of the main targets of mir-155. It is wellestablished that over-expression of miR-155can lead to decrease ofeNOS expression (10, 11) .
Moreover, several studies indicated that post translational alteration of sONE, is one of the mechanisms involved in eNOS regulation. sONEis an anti-sense RNA that is oriented in a tail-to-tail configuration next to NOS3. The region ofsONE and eNOS have 662 nucleotides overlap with each other and sONE gene covers the 3' UTR region of eNOS mRNA (12) . Since the production of NO byeNOS3 is pivotal in different stages of the development of the placenta, such as invasion of trophoblast cells and angiogenesis, it is reasonable to hypothesize that up-regulation of sONE could be one of the main reasons for down-regulation of eNOS3 (13) . Given these, we aimed to evaluate the expression level of mir-155-5p and lncone in the collections of placental tissues of PE women and compare with placental tissues of normalpregnant women. total RNA using gene-specificprimers (Table 1) .
Materials and methods

Study population
cDNA synthesis was performed by reverse specific primers by a method referred to as adapter method.
At first, reverse transcription reactions contained7. 
Results
Patients
In this study the average age and body mass index (BMI) in PE woman were: 27.42 ± 6.7 years, and 23.87 ± 4.15, respectively, and 25.90 ± 3.96 years, and 23.33 ± 2.53, respectively for control group. No significant differences were identified between the normal pregnant and the PE patients with respect to maternal age, but the P-value for BMI was significant (P<0.001) ( Table 2 ).
Placental expression of miR-155-5p and lncone
Increases in miR-155-5p expression in placental tissue from patients with PE (mean± SEM, 4.71 ± 0.24) was 1.6 fold and was found to be significantly higher than the normotensive control group (mean± SEM, 5.55± 0.34; P=0.04; Figure 2 .
A and Figure 3) . for each patient separately (per case), it was found that, in 74.6% of patients, the expression of mir-155-5p was more than one. B: lncsONE expression change between the PE and control groups (mean ± SEM: 4.48±0.20, 4.45±0.23, respectively). By examining 2 ^ -ΔΔct for each patient separately (per case), it was found that, in 47.5% of patients, the expression of lncsONE was more than one. FC: fold change. 
